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Introduction
Skeletal muscle is composed of multinucleated myofi  bers that 
form through the process of myogenesis. During myogenesis, 
myoblasts must exit the cell cycle and subsequently undergo 
differentiation and cell–cell fusion to form myofi  bers in vivo or 
myotubes in vitro. Myoblast fusion follows an ordered set of 
cellular events, including cell migration, adhesion, and mem-
brane fusion (Knudsen and Horwitz, 1977). Myoblast fusion is 
important not only for skeletal muscle formation during devel-
opment but also for the postnatal regeneration and growth of 
skeletal muscle.
Mammalian myoblast fusion occurs in two phases 
  (Horsley and Pavlath, 2004). Initially, myoblasts fuse with 
one another to form small, nascent myotubes. Additional myo-
blasts subsequently fuse with nascent myotubes, leading to the 
formation of large, mature myotubes. Although several mole-
cules regulating the fi  rst phase of fusion have been identifi  ed, 
few molecules specifi  cally regulating the fusion of myoblasts 
with nascent myotubes are known (Horsley and Pavlath, 2004). 
  Molecules implicated to function during the second stage of 
  fusion include secreted proteins and membrane bound proteins, 
as well as transcription factors. Follistatin (Iezzi et al., 2004), 
prostaglandin F2α (Horsley and Pavlath, 2003), and interleu-
kin-4 (IL-4; Horsley et al., 2003) are secreted by muscle cells 
and enhance the growth of nascent myotubes. Prostaglandin 
F2α–mediated growth is dependent on the transcription factor 
NFATC2 (nuclear factor of activated T cells, cytoplasmic, cal-
cineurin-dependent 2; Horsley et al., 2001), and NFATC2 regu-
lates expression of IL-4 (Horsley et al., 2003). IL-4 is secreted by 
a subset of nascent myotubes and acts on unfused cells, leading 
to their recruitment and fusion with nascent myotubes. In addi-
tion, an unknown secreted factor is responsible for mammalian 
target of rapamycin’s actions in regulating   myoblast–myotube 
fusion (Park and Chen, 2005). Membrane bound proteins are 
also important, as myoferlin, a protein localized to the intracel-
lular region of the plasma membrane, is required for the forma-
tion of large myotubes (Doherty et al., 2005). Finally, the lectin 
wheat germ agglutinin inhibits the second stage of fusion in 
vitro (Muroya et al., 1994), suggesting that carbohydrate bind-
ing proteins likely play an important role during this phase of 
fusion. The mechanisms by which these molecules regulate the 
second stage of myoblast fusion have not been identifi  ed.
The mannose receptor (MR) is a 175-kD type 1 trans-
membrane protein that binds a variety of soluble and cell sur-
face glycoproteins (Otter et al., 1991; Pontow et al., 1992; 
Martinez-Pomares and Gordon, 1999; Linehan et al., 2001; 
Martinez-Pomares et al., 2001) and is one of four members of 
the MR family of proteins (East and Isacke, 2002). The extra-
cellular region of MR consists of three types of domains: an 
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N-terminal cysteine-rich domain that confers MR’s ability to 
bind sulfated sugars (Fiete et al., 1998), a region of fi  bronectin 
type II repeats responsible for binding collagen (East and Isacke, 
2002; Martinez-Pomares et al., 2006; Napper et al., 2006), and 
eight carbohydrate recognition domains, providing terminal 
mannose, fucose, N-acetylglucosamine, and glucose binding 
ability in a calcium-dependent manner (Taylor et al., 1992). MR 
is an endocytic receptor and contains a 45-amino-acid cytoplas-
mic region thought to be responsible for receptor internalization 
(Kruskal et al., 1992). MR is expressed in a variety of tissues 
and has been proposed to function in serum glycoprotein clear-
ance, antigen transport and presentation, and immune cell rec-
ognition of foreign microbes (Ezekowitz et al., 1991; Schlesinger, 
1993; Martinez-Pomares and Gordon, 1999; Lee et al., 2002). 
Several lines of indirect evidence have suggested that terminal 
mannose residues or MR may function in cell fusion. MR ex-
pression increases in hematopoietic precursors undergoing dif-
ferentiation and peaks during cell fusion to form osteoclasts or 
multinucleated giant cells (Morishima et al., 2003). High man-
nose mannan, which binds MR with high affi  nity, inhibits the 
fusion of macrophages during multinucleated giant cell forma-
tion in vitro (McNally et al., 1996). In addition, the mannose 
binding compound pradimicin and an inhibitor of glucosidase I, 
an enzyme required for high mannose oligosaccharide expres-
sion, prevent the fusion of hematopoietic precursor cells during 
osteoclast formation (Kurachi et al., 1994; Morishima et al., 
2003). MR also functions in cell–cell adhesion, as antibodies 
that recognize MR inhibit lymphocyte adhesion to endothelial 
cells in vitro (Irjala et al., 2003).
IL-4 signaling regulates MR expression in several cell 
types (Stein et al., 1992; Sallusto et al., 1995; Linehan et al., 
2003; Martinez-Pomares et al., 2003; Zimmer et al., 2003). 
  Because IL-4 is a known regulator of myoblast fusion and be-
cause carbohydrate binding proteins have been implicated in fu-
sion, we hypothesized that MR may have an important function 
during myogenesis. Here, we demonstrate that MR is required for 
myoblast fusion with nascent myotubes in vitro and for proper 
skeletal muscle growth in vivo. We also provide the fi  rst evidence 
that MR plays an important role in cell motility, as MR
−/− cells 
have impaired migratory speed during myoblast fusion in vitro. 
In addition, we show that the collagen uptake is impaired in 
MR
−/− cells and that MR is required for directed cell migration 
during myotube growth. Importantly, these data identify a novel 
function for MR during skeletal muscle growth and have a broad 
implication for MR regulation of cell motility.
Results
MR is expressed during myoblast fusion
To determine whether MR is expressed in muscle cells during 
fusion, myoblasts were induced to differentiate by switching to 
differentiation media (DM) for 0, 24, or 48 h. After 24 h in DM, 
myoblasts fused to form small, nascent myotubes, and after 48 h, 
large myotubes had formed (Fig. 1 A). RT-PCR analyses re-
vealed that MR mRNA levels increased after the onset of myo-
blast fusion and remained elevated at 48 h (Fig. 1 A). RT-PCR 
analyses of myogenin expression, a marker of myogenic differ-
entiation (Wright et al., 1989), demonstrated that the increase in 
MR expression was concurrent with the onset of differentiation. 
Immunostaining of muscle cells after 24 h in DM with an 
  antibody against the intracellular portion of MR (Burudi and 
Regnier-Vigouroux, 2001) revealed that MR protein was present 
in both mononucleated cells and nascent myotubes (Fig. 1 B). 
No immunostaining was present in MR
−/− muscle cells 
(Lee et al., 2002), indicating the specifi  city of the antibody.
IL-4 signaling regulates MR expression in several cell 
types (Stein et al., 1992; Sallusto et al., 1995; Linehan et al., 
2003; Martinez-Pomares et al., 2003; Zimmer et al., 2003). 
IL-4–mediated regulation of MR expression in muscle cells was 
assessed in two experiments. First, nascent myotubes were 
treated with recombinant IL-4 for 24 h. RT-PCR analyses indi-
cated that MR mRNA levels increased in myotubes treated with 
Figure 1.  MR is expressed in muscle cells during myoblast fusion. (A) Pri-
mary myoblasts (Mb) were induced to differentiate for 24 or 48 h. MR 
mRNA was analyzed by RT-PCR. Myogenin mRNA was assessed as a 
marker of myogenic differentiation. Phase-contrast images of muscle cells 
are shown to illustrate fusion progress at each time point. MR, 390 bp; 
Myogenin, 266 bp; 18S, 488 bp. (B) Representative images of muscle 
cells after 24 h of differentiation immunostained with an antibody against 
MR. Bar, 50 μm. (C) Primary myoblasts were differentiated for 24 h and 
subsequently treated with vehicle or 10 ng/ml IL-4 for 24 h. MR mRNA was 
analyzed by RT-PCR. (D) MR mRNA expression in WT or IL-4 receptor α-null 
(IL-4Rα
−/−) myotubes after 48 h in DM was examined by RT-PCR. MR, 
390 bp; 18S, 488 bp. Representative ethidium bromide staining of aga-
rose gels is shown with 18S ribosomal RNA as an internal control for all 
RT-PCR analyses. All data are indicative of results from three independent 
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IL-4 (Fig. 1 C). Conversely, MR mRNA expression was reduced 
in myotubes defi  cient of the IL-4 receptor (Fig. 1 D, IL-4Rα
−/−). 
Together, these data suggest that IL-4 signaling regulates MR 
expression in fusing myoblasts.
MR is required for the second stage 
of myoblast fusion
To test the hypothesis that MR is involved in myoblast fusion, 
we examined the ability of myoblasts derived from wild-type 
(WT) or MR
−/− mice (Lee et al., 2002) to form myotubes 
in vitro. After 20 or 48 h in DM, cells were immunostained with 
an antibody against embryonic myosin heavy chain (eMyHC; 
Fig. 2 A), marking the cytoplasm of differentiated muscle cells 
and clearly defi  ning the nuclei of myotubes. After 20 h in DM, 
MR
−/− myoblasts fused to form small myotubes indistinguish-
able from WT myotubes. However, by 48 h in DM, WT myo-
blasts formed large myotubes, whereas MR
−/− myotubes 
remained small. The impaired growth of MR
−/− myotubes could 
arise from several factors, including defects in proliferation, 
  differentiation, or fusion. To assess the requirement of MR in 
myoblast proliferation, WT and MR
−/− myoblasts were pulsed 
for 1 h with BrdU. The percentage of BrdU
+ cells was similar in 
WT and MR
−/− cells, indicating that MR is not required for 
myoblast proliferation (Fig. S1 A, available at http://www.jcb.
org/cgi/content/full/jcb.200601102/DC1). To determine whether
MR
−/− myoblasts underwent impaired or delayed differentia-
tion, we assessed expression of two markers of myogenic dif-
ferentiation. Immunoblots were performed to examine myogenin 
expression at 16 h in DM, before myoblast fusion. WT and 
MR
−/− cells expressed similar levels of myogenin (Fig. 2 B), 
demonstrating that early stages of myogenic differentiation 
were not disrupted in MR
−/− cells. The percentage of nuclei 
found in eMyHC
+ cells after 48 h in DM was not decreased in 
MR
−/− cells (Fig. 2 C), indicating that MR is not required for 
the later stages of myogenic differentiation. In addition, similar 
numbers of nuclei were present in WT and MR
−/− cultures after 
48 h in DM (Fig. S1 B), indicating that cell survival is not dis-
rupted in MR
−/− cells during differentiation and fusion.
To determine whether MR
−/− myoblasts form small my-
otubes as a result of defects in myoblast fusion, two types of 
fusion analyses were performed. The fusion indices were cal-
culated as the percentage of nuclei located in myotubes (≥2 
nuclei) after 48 h in DM and were similar for WT and MR
−/− 
cells (Fig. 2 D), indicating that MR
−/− cells do not have 
a general defect in myoblast fusion. The number of nuclei 
contained within WT and MR
−/− myotubes was next quanti-
fi  ed (Fig. 2 E). After 20 h in DM, MR
−/− myotubes contained 
the same mean number of nuclei as WT myotubes, indicating 
that the fi  rst stage of myoblast fusion is not disrupted in MR
−/− 
cells. After 48 h in DM, however, MR
−/− myotubes contained 
signifi  cantly fewer nuclei than WT myotubes. Importantly, 
MR
−/− cells do not form small myotubes as a result of delayed 
myoblast fusion, as the number of nuclei in MR
−/− myotubes 
remained low, even after 72 h in DM. These data suggest that 
MR is required for the second stage of myoblast fusion, dur-
ing which myoblasts fuse with nascent myotubes (Horsley 
and Pavlath, 2004).
MR is required for normal skeletal 
muscle growth
Our in vitro data establish a role for MR during myoblast 
  fusion. To determine whether MR plays a functional role in 
skeletal muscle in vivo, we examined myofi  ber size in WT and 
MR
−/− muscles. The tibialis anterior (TA) muscles were col-
lected from adult WT and MR
−/− mice, and sections were 
stained with hematoxylin and eosin (H&E; Fig. 3 A). As con-
fi   rmed by cross-sectional area (XSA) analyses (Fig. 3 B), 
MR
−/− myofi  bers were signifi  cantly smaller than WT myofi  bers. 
In addition, WT muscles contained a higher percentage of large 
myofi  bers, whereas MR
−/− muscles contained a higher per-
centage of small myofi  bers (Fig. 3 C). Myonuclear number 
analyses were performed (Horsley et al., 2001; Mitchell and 
Pavlath, 2001) on TA muscle sections to determine whether 
MR
−/− myofi  bers contain fewer myonuclei than WT myofi  -
bers, as was observed in myotubes in vitro. MR
−/− myofi  bers 
contained signifi  cantly fewer myonuclei than WT myofi  bers 
(Fig. 3 D), suggesting that the reduced XSA of MR
−/− myofi  -
bers is at least partially due to a decrease in myonuclear num-
ber (Allen et al., 1999). XSA analyses were also performed 
on WT and MR
−/− soleus muscles to ensure that the reduced 
myofi  ber size was not specifi  c to the TA. Mean myofi  ber XSA 
was also signifi   cantly reduced in MR
−/− soleus muscles 
(Fig. 3 E). However, the number of myofi  bers in MR
−/− soleus 
muscles was not signifi  cantly different than WT (Fig. 3 F). 
Figure 2.  MR is required for the second phase of myoblast fusion in vitro. 
(A) WT and MR
−/− myoblasts were induced to differentiate in DM for 
20 or 48 h, followed by immunostaining for eMyHC. Bar, 60 μm. (B) Myo-
genin levels in WT and MR
−/− cells were assessed by immunoblot analysis 
of cell lysates collected after 0 or 16 h in DM. Coomassie staining of the 
membrane is shown to demonstrate equal loading. (C) The percentage of 
nuclei within eMyHC
+ WT and MR
−/− cells was calculated after 48 h in 
DM. (D) The percentage of nuclei within WT and MR
−/− myotubes (≥2 
  nuclei) was calculated after 48 h in DM. (E) The number of nuclei in indi-
vidual WT and MR
−/− myotubes (≥2 nuclei) was analyzed after 20, 48, 
or 72 h in DM. The mean number of myonuclei is decreased in MR
−/− 
myotubes compared with WT at 48 h. Data are mean ± SEM for three 
independent cell isolates. *, P < 0.05.JCB • VOLUME 174 • NUMBER 3 • 2006  406
Together, these data suggest that MR is required for develop-
mental muscle growth or maintenance in vivo.
To examine MR function specifi  cally in skeletal muscle 
growth, we analyzed myofi  ber growth in WT and MR
−/− mice 
after muscle injury. BaCl2 was injected into the TA muscles of 
adult mice to induce injury (Caldwell et al., 1990; McArdle 
et al., 1994). After 5, 7, and 14 d of regeneration, muscles were 
collected, sectioned, and stained with H&E (Fig. 4 A). XSA an-
alyses revealed that WT and MR
−/− myofi  bers were similar in 
size at early stages of muscle repair (5 d after injury), but MR
−/− 
myofi  bers were impaired in growth at later stages (7–14 d after 
injury; Fig. 4 B). By 14 d of regeneration, both WT and MR
−/− 
myofi  bers had returned to their respective uninjured size. These 
data provide further evidence for the requirement of MR func-
tion during the later stages of muscle growth.
MR acts in mononucleated cells during 
fusion with nascent myotubes
MR may function in mononucleated cells and/or nascent myo-
tubes during the second stage of myoblast fusion. If MR func-
tions in mononucleated cells, MR
−/− mononucleated cells 
should not be recruited to fuse with WT nascent myotubes. To 
test this hypothesis, WT nascent myotubes were cocultured 
with MR
−/− mononucleated cells in DM for 24 h (Fig. 5 A). 
  Before coculture, each cell population was stained with a fl  uo-
rescent dye (Horsley et al., 2003). After coculture, myotubes were 
analyzed for the presence of both fl  uorescent dyes. Coculture 
of WT nascent myotubes with WT mononucleated cells resulted 
in 77% of myotubes containing both fl  uorescent dyes (Fig. 5 B). 
In contrast, coculture of WT nascent myotubes with MR
−/− 
mononucleated cells resulted in only 37% of myotubes con-
taining both fl  uorescent dyes, indicating that MR
−/− mono-
nucleated cells are impaired in their ability to fuse with nascent 
myotubes. To determine whether MR functions in nascent myo-
tubes, MR
−/− nascent myotubes were cocultured with WT 
mononucleated cells. After coculture,  63% of myotubes con-
tained both fl  uorescent dyes. These results are not statistically 
different from WT/WT coculture, suggesting that MR function 
is not also required in nascent myotubes. To confi  rm the re-
quirement of MR function during the second stage of fusion, we 
cocultured MR
−/− nascent myotubes with MR
−/− mononucle-
ated cells. As expected, MR defi  ciency led to a signifi  cant re-
duction in myoblast fusion with nascent myotubes, as only 32% 
of myotubes contained both fl  uorescent dyes. Together, these 
Figure 3. Myoﬁ   ber XSA and myonuclear 
number are decreased in MR
−/− muscle. 
(A) Representative sections of WT and MR
−/− 
TA muscles stained with H&E. Bar, 60 μm. 
(B) Mean myoﬁ  ber XSA was calculated for WT 
and MR
−/− TA muscles. The mean XSA of 
MR
−/− TA myoﬁ  bers is reduced by 23% com-
pared with WT. Data are mean ± SEM. 
n = 5–6 per genotype. *, P < 0.01. (C) Fre-
quency histogram showing the distribution of 
myoﬁ  ber XSA in WT (n = 943 myoﬁ  bers) and 
MR
−/− ( n  = 1,057 myoﬁ   bers) TA muscles. 
(D) The mean myonuclear number of MR
−/− TA 
myoﬁ  bers is reduced by  34% compared with 
WT. Data are mean ± SEM. n = 5 for each 
genotype. *, P < 0.05. (E) Mean myoﬁ  ber 
XSA was calculated for WT and MR
−/− soleus 
muscles. The mean XSA of MR
−/− soleus myo-
ﬁ  bers is reduced by 14% compared with WT. 
Data are mean ± SEM. n = 5 for each genotype. *, P < 0.05. (F) No difference is observed in the mean number of myoﬁ  bers per soleus muscle of WT 
and MR
−/− mice. Data are mean ± SEM. n = 5 for each genotype.
Figure 4.  MR is required for normal muscle regeneration after injury. 
(A) At days 7 and 14 after BaCl2 injury, WT and MR
−/− TA sections were 
stained with H&E. Representative sections are shown. Bar, 50 μm. (B) The 
XSA of regenerating myoﬁ  bers was analyzed 5, 7, or 14 d after injury. The 
mean XSA of MR
−/− myoﬁ  bers 7 and 14 d after injury is signiﬁ  cantly re-
duced compared with WT. Data are mean ± SEM. n = 5–6 per time point 
for each genotype. *, P < 0.001.MR REGULATES MUSCLE CELL MOTILITY AND GROWTH • JANSEN AND PAVLATH 407
data suggest that mononucleated cells are the primary site of 
MR function during their fusion with nascent myotubes.
To determine whether the impaired ability of MR
−/− 
mononu  cleated cells to fuse with nascent myotubes results spe-
cifi  cally from a loss of MR function, MR expression was restored 
in MR
−/− muscle cells via retroviral infection (Martinez-Pomares 
et al., 2003). Coculture of MR
−/− mononucleated cells infected 
with a MR retrovirus (RV) signifi  cantly increased the ability of 
these cells to fuse with WT nascent myotubes compared with 
MR
−/− mononucleated cells infected with a control RV (Fig. 5 C). 
Together, these results indicate that MR is required for proper 
fusion of mononucleated cells with nascent myotubes.
MR inﬂ  uences myogenic cell motility
We hypothesized that MR may regulate the second stage of myo-
blast fusion by infl  uencing cell–cell adhesion or cell motility. 
Cell–cell adhesion assays indicated that MR
−/− muscle cells 
were not defective in their ability to adhere with one another in 
suspension (unpublished data). To determine whether MR regu-
lates muscle cell motility, we performed time-lapse microscopy 
of WT and MR
−/− cells undergoing fusion in vitro. After 0 or 
24 h in DM, cell movements were recorded every 5 min for 3 h. 
The paths of individual mononucleated cells were tracked, 
  revealing that WT cells migrated farther than MR
−/− cells 
(Fig. 6 A). Additionally, the mean velocity of MR
−/− cells was 
reduced 23% compared with WT cells after 24 h in DM 
(Fig. 6 B), with a greater percentage of WT cells migrating 
at high velocities compared with MR
−/− cells (Fig. 6 C). 
  Importantly, retroviral-mediated MR expression in MR
−/− cells 
signifi  cantly increased the mean cell velocity compared with 
MR
−/− cells infected with a control RV (Fig. 6 D). To ensure 
that retroviral infection of myoblasts does not alter cell motility, 
we assessed the migration of control or RV-infected WT cells 
after 24 h in DM. The motility of RV-infected cells was not 
  disrupted (Fig. S2, available at http://www.jcb.org/cgi/content/
full/jcb.200601102/DC1), suggesting that the differences in cell 
velocity shown in Fig. 6 (B and D) are due to variability be-
tween sets of cell isolates and not the infection process. The 
mean velocity of MR
−/− cells before the fi  rst stage of myoblast 
fusion (0–3 h in DM) was not signifi  cantly different from WT 
(Fig. 6 B). These data demonstrate the requirement of MR for 
effi  cient motility of myogenic cells during their fusion with 
 nascent  myotubes.
MR is required for directed migration 
and collagen uptake
The decreased velocity of MR
−/− cells during myoblast fusion 
may result from a defect in random or directed cell migration. 
To distinguish between these possibilities, we tested the ability 
of MR
−/− cells to respond to a chemotactic gradient. If MR is 
required for a directional response of muscle cells to a chemoat-
tractant during myotube growth, we reasoned that such a factor 
should be present in conditioned media from nascent myotube 
cultures. Dunn chemotaxis chambers were used to establish a 
gradient of conditioned media, and the migratory response of 
muscle cells was observed over 3 h by time-lapse microscopy. 
The paths of individual cells were tracked, and the fi  nal location 
of each cell in relation to its origin was determined. Directional 
data were summarized in circular histograms, and statistical 
tests revealed that WT but not MR
−/− cells migrated up a gradi-
ent of conditioned media (Fig. 7 A). Conditioned media also 
contains chemokinetic properties not dependent on MR, as the 
velocity of both WT and MR
−/− cells increased 1.2–1.5-fold in 
the presence of a conditioned media gradient (Fig. 7 B). The 
mean velocity of MR
−/− cells was signifi  cantly lower than WT 
cells in the presence of control or conditioned media, confi  rm-
ing that MR is required for effi  cient motility of muscle cells in 
addition to functioning in directed migration.
The MR family member Endo180 plays a role in both 
directed and random cell migration (East et al., 2003; Sturge 
Figure 5.  MR is required in mononucleated cells for normal fusion with 
nascent myotubes. (A) WT or MR
−/− nascent myotubes were labeled with 
a green ﬂ  uorescent dye and mixed with WT or MR
−/− mononucleated 
cells labeled with a red ﬂ  uorescent dye. After 24 h in DM, myotubes were 
ﬁ  xed and analyzed for dual labeling. A representative myotube with dual 
labels is shown. (B) The percentage of myotubes with dual labels was cal-
culated for each mixing experiment as indicated. The percentage of myo-
tubes with dual labeling was signiﬁ   cantly reduced when WT nascent 
myotubes were mixed with MR
−/− mononucleated cells compared with 
WT mononucleated cells. (C) Retroviral-mediated expression of MR 
(MR RV) in MR
−/− mononucleated cells rescues the defect in fusion with 
WT nascent myotubes. Data are mean ± SEM for three independent cell 
isolates. *, P < 0.05.JCB • VOLUME 174 • NUMBER 3 • 2006  408
et al., 2003). Endo180 is thought to facilitate cell motility via 
clearance of collagen, a component of the ECM. Degradation of 
the ECM is an important step in facilitating cell migration dur-
ing tissue development, regeneration, and homeostasis (Murphy 
and Gavrilovic, 1999). Recently, MR was shown to bind colla-
gen, most likely through its fi  bronectin type II repeats ( Martinez-
Pomares et al., 2006; Napper et al., 2006). To determine whether 
MR facilitates collagen clearance in muscle cells, we performed 
uptake assays with 
125I-labeled type IV collagen. Differentiating 
MR
−/− muscle cells internalized signifi  cantly less collagen than 
WT cells (Fig. 8). Together, these results demonstrate that MR 
functions in directed migration of muscle cells and suggest that 
MR facilitates cell motility by internalizing collagen during 
myotube growth.
Discussion
Skeletal muscle formation, growth, and regeneration rely on the 
fusion of mononucleated myoblasts with one another and with 
existing myofi  bers. Myoblast fusion is dependent on a series of 
cellular events, including myoblast differentiation, migration, 
adhesion, and membrane breakdown. Disruption of any of these 
processes may inhibit myoblast fusion. The molecular pathways 
regulating myoblast fusion in mammals are largely unclear. 
Here, we show that MR, a type I transmembrane protein, is re-
quired for the normal fusion of myoblasts with nascent myo-
tubes. MR plays an important role in muscle cell motility, as 
MR
−/− myoblasts migrate at reduced velocity during myotube 
growth and directed migration up a chemoattractant gradient is 
ablated. In addition, collagen uptake is impaired, suggesting a 
role for MR in ECM remodeling during cell migration.
Myoblast fusion in mammals occurs in two phases  (Horsley 
and Pavlath, 2004). Initially, myoblasts fuse with one another to 
form small, nascent myotubes. Subsequently, myonuclear accre-
tion occurs through the fusion of additional myoblasts with na-
scent myotubes. Our data indicate that MR is required during the 
second stage of myoblast fusion. Two lines of evidence   suggest 
that MR is not required during the fi  rst phase of myoblast fusion. 
First, at early stages of myotube formation in vitro, WT and 
MR
−/− nascent myotubes contained similar numbers of nuclei 
(Fig. 2). Subsequently, WT myotubes continued to accumulate 
nuclei through additional rounds of myoblast fusion, whereas 
MR
−/− myotubes did not. Second, early phases of regeneration 
in vivo were similar in WT and MR
−/− muscles, but MR
−/− mus-
cles were defective in later stages of muscle regeneration 
(Fig. 4). Furthermore, the myofi  bers of adult MR-null mice were 
signifi  cantly reduced in XSA compared with WT myofi  bers. 
  Importantly, the reduced myofi  ber XSA of MR
−/− mice corre-
lated with a decrease in myonuclear number (Fig. 3). These data 
indicate that the MR is also required for proper developmental 
myofi  ber growth or maintenance in vivo. Thus, MR is necessary 
for the fusion of myoblasts with nascent myotubes/myofi  bers 
both in vitro and in vivo.
Cell mixing experiments demonstrated that MR function 
is required in myoblasts, as MR
−/− myoblasts were defi  cient in 
their ability to fuse with nascent myotubes. This defect was due 
specifi  cally to the loss of MR, as retroviral-mediated MR ex-
pression in MR
−/− myoblasts restored their ability to fuse with 
nascent myotubes (Fig. 5). However, MR protein was present in 
both myoblasts and nascent myotubes at 24 h of differentiation 
in vitro (Fig. 1). This discrepancy between expression and func-
tion may be explained if levels of cell-surface MR protein are 
regulated differentially in myoblasts and myotubes. Members 
of the MR family of proteins are constitutively recycled from 
the plasma membrane, and estimates have been made that only 
 10–30% of total MR protein is present on the cell surface at 
any point in time (East and Isacke, 2002).
What is the cellular mechanism by which MR acts in 
  myoblasts to regulate the second stage of myoblast fusion? We 
hypothesized that MR may function in myogenic cell–cell 
  adhesion or cell migration. MR has previously been implicated 
in adhesion of leukocytes to human lymphatic endothelium via 
interaction with the cell-adhesion molecule l-selectin (Irjala 
et al., 2003). However, MR
−/− myogenic cells were capable of 
Figure 6.  MR is required for efﬁ  cient muscle 
cell motility. (A) After 24 h in DM, time-lapse 
photographs of WT and MR
−/− cells were 
taken every 5 min for 3 h. The migratory paths 
of individual mononucleated cells are shown. 
Paths of 10 cells from each of three indepen-
dent cell isolates for each genotype were 
pooled for a total of 30 cell paths. (B) The 
mean velocities of WT and MR
−/− cells were 
pooled from three independent cell isolates at 
0–3 h or 24–27 h in DM. The mean velocity of 
MR
−/− cells is reduced by 23% compared with 
WT from 24–27 h in DM. Data are mean ± SEM. 
n  = 45–50 cells. *, P < 0.0001. (C) Fre-
quency histogram showing the distribution of 
velocities for WT and MR
−/− cells. (D) MR
−/− 
cells were infected with control or MR RV. After 
24 h in DM, time-lapse photographs were 
taken every 5 min for 3 h. The mean velocities 
were pooled from three independent cell iso-
lates. RV-mediated MR expression signiﬁ  cantly 
increases the velocity of MR
−/− cells. Data are 
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adhering to one another in suspension-based assays (Knudsen 
and Horwitz, 1977; Gibralter and Turner, 1985; Knudsen, 1985; 
Knudsen et al., 1989). In contrast, MR
−/− myoblasts displayed 
decreased velocity and distance of migration during myotube 
growth (Fig. 6). Importantly, restoration of MR expression via 
retroviral infection of MR
−/− cells signifi  cantly increased the 
velocity of MR
−/− cells, indicating that MR is required for effi  -
cient myoblast migration. As expected, the migration of MR
−/− 
cells was not disrupted at early times in DM, as MR mRNA 
levels were very low (Fig. 1) and protein levels were undetect-
able (not depicted) at the initiation of differentiation. These 
data are in agreement with the fi  ndings that MR is not required 
for the fi  rst phase of fusion. Interestingly, a protein related to 
MR, Endo180 (also referred to as urokinase-type plasminogen 
activator receptor–associated protein, or UPARAP) is required 
for effi  cient motility of fi  broblasts, suggesting that members of 
the MR family of proteins may share a common role in facilitat-
ing cell migration (East et al., 2003; Engelholm et al., 2003). 
These data provide the fi  rst evidence that MR plays a role in 
cell motility.
Cell migration during tissue development and remod-
eling involves both a directed cellular response to chemo-
attractant factors and the breakdown of the ECM (Murphy and 
Gavrilovic, 1999; Ridley et al., 2003). Degradation of the ECM 
by extracellular proteolytic enzymes facilitates cell motility, 
whereas chemotaxis involves the movement of cells to a spe-
cifi  c location in response to directional signals. Our data reveal 
that MR is required for the directed migration of muscle cells 
up a conditioned media gradient (Fig. 7). We propose that na-
scent myotubes secrete factors necessary for the directed mi-
gration of myoblasts during fusion and that MR is required for 
the directional response of cells to at least one of these   factors. 
The factors responsible for MR-dependent chemotaxis are un-
known. A chemoattractant may bind the extracellular region of 
MR directly. Engagement of the MR by an extracellular ligand 
may initiate an intracellular signaling cascade necessary for 
providing directional cues to the cell. However, no character-
ized signaling domains have been identifi  ed in the MR cyto-
plasmic tail. Alternatively, MR may act as a coreceptor for a 
chemoattractant. For example, Endo180 interaction with the 
GPI-anchored urokinase plasminogen activator receptor is 
required for directed cell migration up a urokinase plasmino-
gen activator gradient (Sturge et al., 2003). The mechanism by 
which MR mediates directed muscle cell migration is currently 
under investigation.
In addition to impaired directional migration, MR
−/− cells 
migrated at a reduced velocity during myoblast fusion (Fig. 6) 
and in the presence of control or conditioned media (Fig. 7). 
These data suggest that MR may also facilitate the random mo-
tility of muscle cells. Endo180 is thought to facilitate the motil-
ity of fi  broblasts via clearance of the ECM component collagen 
(East et al., 2003). MR has recently been shown to bind several 
forms of collagen, and internalization of collagen IV by macro-
phages is dependent on the presence of MR (Martinez-Pomares 
et al., 2006; Napper et al., 2006). Our results revealed that 
MR
−/− muscle cells were impaired in the uptake of type IV col-
lagen (Fig. 8). However, unlike MR
−/− macrophages, collagen 
uptake was not ablated in MR
−/− muscle cells. Endo180, which 
is expressed in fusing muscle cells (unpublished data), may en-
able the uptake of collagen in the absence of MR. We hypothe-
size that MR regulates cell motility by facilitating collagen 
clearance by muscle cells.
Figure 7.  MR is required for directional migration up a gradient of 
conditioned media. WT or MR
−/− cells were differentiated for 24 h and 
assayed for migration in Dunn chemotaxis chambers. Cell migration over 
3 h was recorded using time-lapse photography in the presence of con-
trol media or a gradient of conditioned media (CM). For each genotype, 
data were pooled from three independent isolates. (A) Cell directionality 
was determined using the horizon distance method and the Rayleigh test 
for unimodal clustering. The circular histograms indicate the proportion 
of cells with a migratory trajectory lying within each 18° interval. The 
mean direction and 95% conﬁ   dence intervals (red line and arc) are 
shown for conditions in which signiﬁ   cant clustering of cell migration 
  occurs. The directionalities of 45 cells were analyzed in each condition, 
and graphs depict data from 23 cells. (B) The mean velocity of MR
−/− 
cells was 37% lower than WT cells in control media and 29% lower in 
conditioned media. Data are mean ± SEM. n = 45–50 cells for each 
condition. *, P < 0.05.
Figure 8.  Collagen uptake is reduced in MR-null muscle cells. After differ-
entiating for 24 h, WT and MR
−/− cells were incubated with 1 nM 
125I-labeled type IV collagen in DM for 4 h. Cell surface bound collagen 
was released by collagenase treatment, and internalized collagen was as-
sessed using a gamma counter and expressed as counts per minute (cpm). 
Collagen internalization is reduced by 30% in MR
−/− cells. Data are 
mean ± SEM for three independent cell isolates. *, P < 0.05.JCB • VOLUME 174 • NUMBER 3 • 2006  410
Although MR
−/− cells migrated at a reduced velocity, their 
migration was not ablated, suggesting that additional migratory 
signals are functioning in the absence of MR. The migration of 
muscle precursor cells during embryonic development and post-
natal regeneration is essential to the formation and maintenance 
of mammalian skeletal muscle. A variety of molecules, including 
growth factors, cytokines, chemokines, ECM components, pro-
teolytic enzymes, and intracellular signaling proteins have been 
implicated in cell migration. Hepatocyte growth factor (HGF) and 
its receptor, c-Met, are required for the migration of muscle pre-
cursor cells from the dermomyotome to the limbs (Birchmeier and 
Brohmann, 2000). Several growth factors, including HGF, bFGF, 
PDGF A and B, LIF (leukemia inhibitory factor), TGF-β, and 
IGF-1 (insulin-like growth factor I) induce myoblast migration 
in vitro (Robertson et al., 1993; Bischoff, 1997; Suzuki et al., 2000). 
The cytokines TNF-α and IFN-γ and the chemokine RANTES 
also enhance myoblast migration in vitro (Bischoff, 1997; Corti 
et al., 2001). ECM components such as laminin (Goodman et al., 
1989) and proteoglycans (  Olguin et al., 2003) as well as extra-
cellular proteolytic enzymes, including matrix metalloproteinases 
and calpain (El Fahime et al., 2000; Dedieu et al., 2004), infl  uence 
myoblast motility. Studies of intracellular signaling pathways in-
volved in myoblast migration indicate that HGF induces myoblast 
migration via activation of Ras and phosphatidylinositol 3-kinase 
and their downstream effectors (Suzuki et al., 2000; Kawamura 
et al., 2004). The precise relationship among these various mol-
ecules during myoblast migration remains unclear.
Our results suggest, but do not directly prove, the impor-
tance of myoblast migration for myotube growth. Further roles 
for MR may contribute to the defect in the fusion of MR
−/− my-
oblasts with nascent myotubes. For example, MR may regulate 
cell–cell interactions among myogenic cells. MR is known to 
bind a variety of glycosylated proteins in other cell types and 
may aid in the recognition of myoblasts and myotubes by inter-
acting with a ligand or ligands on the surface of opposing cells. 
Identifi  cation of MR ligands in skeletal muscle will provide fur-
ther insight into the mechanisms by which muscle growth is 
regulated. Understanding the molecular pathways involved in 
myoblast migration, adhesion, and fusion is important in de-
signing treatments for impaired muscle growth associated with 
age, disease, and atrophy. In addition, promotion of cell fusion 
may aid in cell therapy protocols using exogenous stem cells 
(Seale et al., 2001; Smythe et al., 2001).
Materials and methods
Animals
MR
−/− mice produced on the 129vJ × C57BL/6 background and back-
crossed to C57BL/6 mice for seven generations were provided by 
M.   Nussenzweig (The Rockefeller University, New York, NY; Lee et al., 
2002). Additional MR
−/− mice were generated by homozygous matings. 
Control age- and sex-matched C57BL/6 mice were purchased from Charles 
River Laboratories. Adult mice between 8–12 wk of age were used for all 
studies. All animals were handled in accordance with the institutional 
guidelines of Emory University.
Primary muscle cell culture and cytokine treatment
Primary myoblasts were derived from the hindlimb muscles of adult female 
WT or MR
−/− mice as previously described with the exception of a percoll 
gradient (Mitchell and Pavlath, 2001; Bondesen et al., 2004). In brief, 
muscles were minced mechanically and digested with 0.1% pronase 
  (Calbiochem) in DME containing 25 mM Hepes at 37°C with slight agita-
tion for 1 h. The muscles were further dissociated by trituration and 
passed through a 100-μm ﬁ  lter. Cells were suspended in growth media 
(GM; Ham’s F10, 20% FBS, 5 ng/ml bFGF, 100 U/ml penicillin G, and 
100 μg/ml streptomycin) and grown on collagen-coated dishes in a hu-
midiﬁ  ed 5% CO2 incubator at 37°C. Primary cultures were enriched for 
myogenic cells to >99% purity using the preplating technique as described 
previously (Rando and Blau, 1994). To induce differentiation, cells were 
plated on dishes coated with entactin–collagen IV–laminin (E-C-L; Upstate 
Biotechnology) in GM and shortly thereafter switched to DM (DME, 1% 
  Insulin-Transferrin-Selenium-A supplement [Invitrogen], 100 U/ml penicillin G, 
and 100 μg/ml streptomycin). For analysis of MR mRNA expression, WT 
and IL-4Rα
−/− were derived and grown as described previously (Horsley 
et al., 2003). In experiments using exogenous cytokines, vehicle or 
10 ng/ml recombinant mouse IL-4 (R&D Systems) was added to cells after 
24 h in DM and RNA was isolated 24 h later.
RT-PCR analyses
RNA was isolated from primary muscle cells using TRIzol reagent (Life Tech-
nologies) according to the manufacturer’s instructions. Reverse-  transcriptase 
reactions were performed using 2.5 μg of total RNA. cDNA was ampliﬁ  ed 
using Expand High Fidelity PCR system (Roche) with primers speciﬁ  c for 
MR (available under GenBank/EMBL/DDBJ under accession no. NM_
008625; sense, 5′ A  G  T  G  A  T  G  G  T  T  C  T  C  C  C  G  T  T  T  C  C  T  A  T  ; antisense, 5′ T  G  A-
C  T  G  C  C  C  A  C  C  A  T  T  C  T  T  G  T  T  T  A  T  ) or myogenin (accession no. NM_031189; 
sense, 5′ A  G  C  G  G  C  T  G  C  C  T  A  A  A  G  T  G  G  A  G  A  T  ; antisense, 5′ G  G  A  C  G  T  A  A-
G  G  G  A  G  T  G  C  A  G  A  T  T  G  T  G  ). All primer pairs spanned intron and exon 
boundaries to control for any contaminating DNA in RNA samples. MR 
cDNA was ampliﬁ  ed by incubation at 94°C for 5 min, followed by 35 cy-
cles of 94°C for 30 s, 54°C for 30 s, and 72°C for 30 s, and terminating 
at 72°C for 5 min, generating a 390-bp amplicon. Myogenin cDNA was 
ampliﬁ  ed by incubation at 94°C for 5 min, followed by 25 cycles of 94°C 
for 30 s, 60°C for 30 s, and 72°C for 30 s, and terminating with 72°C 
for 5 min, generating a 266-bp amplicon. Amplicons were separated by 
electrophoresis in a 1% agarose gel and visualized with ethidium bromide. 
RT-PCR analysis of 18S ribosomal RNA was included as a control for each 
sample using QuantumRNA 18S primers (Ambion).
MR immunocytochemistry
For detection of MR protein by immunoﬂ  uorescence, WT and MR
−/− pri-
mary myoblasts were differentiated for 24 h and subsequently ﬁ  xed  in 
3.7% formaldehyde for 10 min. Cells were then incubated in block buffer 
(PBS containing 0.25% Triton X-100 and 5% donkey serum) for 1 h, fol-
lowed by incubation with a polyclonal antibody recognizing the cytop-
lasmic tail of MR (provided by A. Regnier-Vigouroux, Deutsches 
Krebsforschungszentrum, Heidelberg, Germany; Burudi and Regnier-
  Vigouroux, 2001) diluted 1:500 in block buffer for 1 h. After several 
washes in PBS + 0.2% Tween 20 (PBS-T), the cells were incubated with 
  biotin-conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch Labora-
tories) diluted 1:500 in block buffer for 1 h. Cells were washed with PBS-T 
and subsequently incubated with streptavidin-horseradish peroxidase di-
luted 1:250 in block buffer for 30 min. The Tyramide Signal Ampliﬁ  cation 
green reagent (NEN Life Science Products) was used to visualize antibody 
binding. Fluorescence images were acquired using a microscope (Axiovert 
200M; Carl Zeiss MicroImaging, Inc.) with a 0.3 NA 10× Plan-Neoﬂ  uar 
objective (Carl Zeiss MicroImaging, Inc.) and camera (QImaging) with 
OpenLab 3.1.4 (Improvision). Cells were stored in PBS at room tempera-
ture for all image acquisition. Images were assembled using Photoshop 
7.0 (Adobe) software and were not modiﬁ  ed with the exception of equal 
adjustments in size, brightness, and contrast.
Differentiation and fusion assays
Primary myoblasts from WT and MR
−/− mice were seeded on E-C-L–coated 
6-well dishes at a density of 2 × 10
5 cells/well in GM. Cells were allowed 
to adhere to the dish for  1 h before switching to DM. After 20 or 48 h in 
DM, cells were ﬁ  xed in 3.7% formaldehyde for 10 min and subsequently 
immunostained with an antibody against eMyHC (F1.652; Developmental 
Studies Hybridoma Bank) as described previously (Horsley et al., 2001). 
The differentiation index was determined by dividing the total number of 
nuclei in eMyHC-positive cells by the total number of nuclei counted. The 
mean number of nuclei per myotube was determined by dividing the total 
number of nuclei in myotubes (≥2 nuclei) by the total number of myotubes 
counted. The fusion index was determined by dividing the total number of 
nuclei in myotubes by the total number of nuclei counted. At least 100 
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To assess myogenin expression, three independent WT and MR
−/− 
cell isolates were differentiated for 0 or 16 h and were subsequently lysed 
in RIPA-2 buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% 
deoxycholic acid, and 0.1% SDS) containing protease inhibitors (Mini com-
plete; Roche) for 10 min on ice. Lysates were spun at 21,000 g for 15 min 
at 4°C. Protein concentration was determined using the Bradford assay 
(Bio-Rad Laboratories), and 25 μg of total protein was separated by SDS-
PAGE. After transfer to a polyvinylidene diﬂ  uoride membrane (Millipore), 
myogenin protein was detected using a mouse monoclonal antibody (F5D; 
Developmental Studies Hybridoma Bank) diluted 1:10 in block buffer as 
described previously (Friday and Pavlath, 2001). Membranes were stained 
with Coomassie (Bio-Rad Laboratories) to conﬁ  rm equal loading.
Collection of muscles and morphometric measurements
TA and soleus muscles were collected from adult male mice (n = 5–6) as 
described previously (Horsley et al., 2001). Serial 14-μm sections were 
collected along the entire length of each muscle and stained with H&E. 
  Histological analyses were performed on sections collected from similar re-
gions of each TA muscle and the belly of each soleus muscle. Two images 
were captured from each section, and Scion Image 1.63 (Scion Corp.) 
was used to determine the XSA of 50–100 myoﬁ  bers per ﬁ  eld. All photog-
raphy was performed on a microscope (Axioplan; Carl Zeiss MicroImag-
ing, Inc.) with a 0.3 NA 10× Plan-Neoﬂ   uar objective (Carl Zeiss 
MicroImaging, Inc.) equipped with a charge-coupled device camera (Carl 
Zeiss MicroImaging, Inc.). Pictures were assembled using Photoshop 7.0 
and were not modiﬁ  ed other than adjustments of size, color levels, bright-
ness, and contrast.
In vivo myonuclear number analyses were performed as described 
previously (Horsley et al., 2001). In brief, sections of TA muscles from WT 
and MR
−/− mice (n = 5–6) were immunostained with an antibody against 
dystrophin (MANDYS8; Sigma-Aldrich) to visualize the sarcolemma of 
myoﬁ  bers and mounted in Vectashield mounting media containing DAPI 
(Vector Laboratories) to stain nuclei. Nuclei within dystrophin-positive sar-
colemma were counted for 50–100 myoﬁ  bers, and the number of nuclei 
was expressed per 100 myoﬁ  bers.
To analyze muscle growth during regeneration, injury was induced 
in the TA muscles of WT and MR
−/− mice (n = 5–6) by injection of 50 μl 
of 1.2% BaCl2 diluted in PBS with a 27-gauge needle (Caldwell et al., 
1990; McArdle et al., 1994) along the length of the muscle. Muscles were 
collected 5, 7, or 14 d after injury, and XSA of centrally nucleated regen-
erating ﬁ  bers was assessed as described above.
Retroviral plasmids, production, and infection
A retroviral vector encoding full-length MR (provided by L. Martinez-
  Pomares, Queen’s Medical Center, Nottingham, UK; Martinez-Pomares 
et al., 2003) and a control vector (pFB-neo; Stratagene) were used to pro-
duce infectious retroviral supernatants as described previously (Abbott 
et al., 1998). Primary WT and MR
−/− myoblasts were subjected to two 
rounds of infection (Abbott et al., 1998), and infected cells were selected 
by growing cells with 50 μg/ml of Geneticin (Invitrogen) in GM.
Cell mixing experiments
Cell mixing experiments were performed as described previously with mi-
nor modiﬁ  cations (Horsley et al., 2003). Primary myoblasts were grown 
at low density (0.5 × 10
5 cells per well of a 6-well plate) or high den-
sity (2 × 10
5 cells per well of a 6-well plate) in DM for 24 h to gener-
ate differentiated mononucleated cells or nascent myotubes, respectively. 
Mononucleated cells were incubated with CellTracker Orange CMTMR 
(5-(and-6)-(((4-chloromethyl) benzoyl) amino) tetramethylrhodamine) (Invit-
rogen) diluted to 2.5 μM in DM, and nascent myotubes were incubated 
with CellTracker Green CMFDA (5-chloromethyl-7-hydroxycoumarin; Invit-
rogen) diluted to 0.5 μM in DM for 10 min at 37°C. Cells were washed 
twice with PBS, trypsinized, mixed at equal cell number, and plated to give 
a ﬁ  nal cell number of 2 × 10
5 cells per well of a 6-well E-C-L–coated plate. 
After 24 h in DM, the cells were ﬁ  xed for 10 min in 3.7% formaldehyde. 
The presence of dual label was analyzed in 50–100 myotubes with ≥3 
nuclei. Mixing experiments were performed in triplicate using WT and 
MR
−/− myoblasts from three independent cell isolates.
Cell migration assays
Primary myoblasts were seeded on E-C-L–coated 35-mm plates at a density 
of 2 × 10
5 cells per plate in GM. After allowing cells to adhere for  1 h, 
cells were switched to DM. At 0 or 24 h in DM, 25 mM Hepes was added 
to the cultures and cells were transferred to a microscope stage heated to 
37°C. Cell migration was visualized using a Axiovert 200M microscope 
with a 0.3 NA 10× Plan-Neoﬂ  uar objective (Carl Zeiss MicroImaging, 
Inc.), and images were recorded (QImaging camera and OpenLab 3.1.4 
software) every 5 min for 3 h. Cell velocities were calculated in microme-
ters per hour using ImageJ software by tracking the paths of individual 
mononucleated cells. Cell migration assays were performed for each geno-
type using three independent cell isolates. The mean velocities of 45–50 
cells ( 15 cells per isolate) were pooled and analyzed for statistical signiﬁ  -
cance as described (see Statistics).
Dunn chamber analysis
Permanox plastic cell culture slides (Nunc) were cut into 6-cm
2 squares, 
and an  1-cm
2 region of each slide was coated with E-C-L for 1 h at 
37°C. Primary myoblasts were then seeded at a density of 5 × 10
3 cells 
per slide in GM. Cells were allowed to adhere for 1 h, and GM was re-
placed with DM. The low density at which the cells were plated ensured 
that cells underwent myogenic differentiation with limited cell fusion. 
After 24 h in DM, the Dunn chamber was assembled as described previ-
ously (Zicha et al., 1991, 1997). DM that had been conditioned by dif-
ferentiating primary muscle cells for 24 h was collected before chamber 
assembly and supplemented with 25 mM Hepes. To set up gradient ex-
periments, both concentric wells of the chemotaxis chamber were ﬁ  lled 
with control DM (supplemented with 25 mM Hepes), and the slide con-
taining differentiating cells was inverted onto the chamber to cover both 
wells. The slide was sealed onto the chamber with a hot 1:1:1 mixture of 
parafﬁ  n wax, beeswax, and petroleum jelly, leaving a small slit of the 
outer well open. DM was removed from the outer well and replaced with 
control or conditioned media, and the slit was sealed. After allowing the 
gradient to establish for 30 min at 37°C, a small region over the annular 
bridge was visualized and cell migration was analyzed by time-lapse mi-
croscopy as above (see Cell migration assays). Statistical analyses of 
directional data were performed to assess the chemotactic response of 
the cells as described previously (Zicha et al., 1997). Each cell path was 
converted to a trajectory originating from (0,0) on an x-y axis. A horizon 
distance for each condition was established by determining the distance 
passed by 50% of the cells in a straight line from their starting point. The 
horizon method is designed to assess the directionality of cell movement 
without inﬂ  uence from differences in cell motility. Cells that fail to reach 
the horizon distance were excluded from directional analysis. A trajec-
tory angle for each cell was calculated as the direction of each cell from 
its starting point to the point at which the cell crossed the horizon dis-
tance. The directional data were summarized as circular histograms in 
which the area of each sector represents the proportion of trajectory an-
gles located within each 18° interval. The Rayleigh test for unimodal clus-
tering was applied with P < 0.05 as the criterion for rejecting the null 
hypothesis of uniform distribution. Where unimodal clustering was 
  observed, a mean direction and 95% conﬁ  dence interval were calculated. 
Statistical analysis was performed using Oriana 2.0 (RockWare). Dunn 
chamber assays were performed using three independent cell   isolates. 
Directional analyses were performed using at least 15 cells per assay for 
a total of 45 cells.
Collagen uptake assay
Collagen internalization assays were performed as described previously 
(Engelholm et al., 2003). Type IV collagen (Calbiochem) was labeled 
with 
125I via Iodogen (PerkinElmer), resulting in a speciﬁ   c activity of 
88 μCi/mg. Primary myoblasts were differentiated for 24 h as described 
above (see Differentiation and fusion assays). After 24 h in DM, 1 nM 
125I-collagen was added to the cells. After a 4-h incubation at 37°C, the 
medium was removed and cells were washed twice with PBS to remove 
unbound collagen. Cells were treated with 0.2% type I collagenase 
(Worthington) diluted in 0.05% trypsin and 0.53 mM EDTA (Invitrogen) to 
lift cells and cleave cell surface bound collagen. In pilot experiments, 
0.2% type I collagenase treatment released >95% of cell surface bound 
collagen. The detached cells were centrifuged at 1,000 g for 5 min, and 
the radioactivity of the supernatant (cell surface released collagen) and 
pellet (internalized collagen) was measured using a gamma counter 
(1470 WIZARD; Wallac).
Statistics
To determine signiﬁ  cance between two groups, comparisons were made 
using t tests. Analyses of multiple groups were performed using a two-way 
analysis of variance with Bonferroni’s posttest. Statistical analyses were 
performed using GraphPad Prism 4.0 (GraphPad) for Macintosh or Sigma-
Stat 2.03 (SPSS). For all statistical tests, a conﬁ  dence level of P < 0.05 was 
accepted for statistical signiﬁ  cance.JCB • VOLUME 174 • NUMBER 3 • 2006  412
Online supplemental material
Fig. S1 shows that cell proliferation and cell survival are not disrupted 
in MR
− /− cells. Fig. S2 demonstrates that retroviral infection does not 
alter myoblast motility. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200601102/DC1.
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